The Structural Genomics Consortium is a not-for-profit public-private partnership based at the University of Toronto and Oxford University that engages in pre-competitive basic science research to facilitate and enable the discovery of new medicines. It catalyzes research in new areas of human biology and drug discovery by focusing explicitly on less well-studied areas of the human genome, for example epigenetic signaling pathways.
The SGC accelerates research and drug discovery in these areas by making all of its research output available in the public domain with no restrictions on use and no patent protection, and by creating an open collaborative network of scientists in hundreds of universities around the world and in its nine global pharmaceutical company partners.
To facilitate its various ongoing research projects and to secure its ability to place the results of this research into the public domain to be used freely by others, the SCG is negotiating novel open innovation contracts with various parties within its collaborative ecosystem, including funding agreements with private and public sources of financing; and memorandums of understanding, collaboration agreements, and material transfer agreements with partner research organizations, disease foundations, and scientists.
Students will attend contract negotiations led by experienced intellectual property lawyers; at the direction of the field supervisors and under their supervision, prepare initial and revised drafts of memoranda of understanding, research collaboration agreements, material transfer agreements, and funding agreements that promote the SGS’s open innovation policy; and carry out legal research.
Students will also meet, in a seminar format, with Professors
Stern and Niblett, to discuss readings on patent law and the developing alternatives to conventional patent protection, and with Professor Aled Edwards, who will provide instruction about the background to the SGC initiative and to the open-access movement in medical innovation more generally.